Maintenance Therapies

 

Maintenance Therapies

When your cancer treatment ends, your doctor may want you to receive on-going medication or other treatment to help keep your cancer in remission. This is called maintenance therapy, because its goal is to maintain the effectiveness of the original treatment.

Maintenance therapy is used for various cancers, including lymphoma, breast cancer, lung cancer and leukemia, among others. The selection of a maintenance therapy depends upon cancer type, original treatment and other factors. Some maintenance therapies are well-established regimens; others are being tested in clinical trials.

Although you may feel some reassurance that you’re strengthening your prospects for remission by continuing anticancer medication or other maintenance therapy, it may also leave you feeling a bit like you’re in limbo. Your main treatment has ended, but with maintenance therapy, you may feel more like a patient than like someone who is moving forward.  

Take heart from the fact that maintenance therapy is part of your plan to sustain and strengthen your overall health. You may need to manage cancer long-term as part of that plan, but many people have to do the same with other health conditions, including asthma, heart disease, diabetes and high blood pressure.

Be sure to talk with your doctor about your maintenance therapy program so that you understand its schedule and goals. Just as with primary treatment, discuss questions about your medications or any side effects with your doctor as soon as possible. There are good solutions available for many side effects—solutions that will enable you to continue maintenance therapy and benefit from it.                                    

References

“Life After Treatment.” Caring4Cancer magazine. 2006.

Neumann F, Harmsen S, Martin S, et al. “Rituximab Long-term Maintenance Therapy After Autologous Stem Cell Transplantation in Patients with B-cell non-Hodgkin’s Lymphoma.” Annals of Hematology, 2006, Apr. 26, epub ahead of print.

“Glossary: Maintenance Therapy.” Living Beyond Breast Cancer.  http://www.lbbc.org/search.asp?q=maintenance+therapy&final=1&t=GLOSSARY. Accessed 5/16/06

Mattson K, Niiranen A, Ruotsalainen T, et al. “Interferon Maintenance Therapy for Small Cell Lung Cancer: Improvement in Long-Term Survival.” Journal of Interferon & Cytokine Research, 17(2):103-105, Feb. 1997.

Latest Cancer News
Late Mortality Persists Beyond Five Years in Children with Cancer

October 6, 2008 — Researchers affiliated with the Children’s Oncology Group have reported that children with cancer who survive five years still remain at risk and need continued observation. The details of this study appeared in an early online publication in the Journal of the National Cancer Institute on September 23, 2008.

Addition of Avastin® to Tarceva® Does Not Appear to Improve Survival in Patients with Advanced Non–Small Cell Lung Cancer

October 6, 2008 — According to the results of a Phase III clinical trial, treatment with Avastin® (bevacizumab) plus Tarceva® (erlotinib) did not result in better survival than treatment with Tarceva alone among patients with advanced non–small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy. These results were recently published in a press release by Genentech.

Possible Link between Hepatitis B Virus and Pancreatic Cancer

October 6, 2008 — Researchers from the M. D. Anderson Cancer Center in Texas have reported that exposure to the hepatitis B virus may be associated with the development of pancreatic cancer. The study was recently published in the October 1, 2008 issue of the Journal of Clinical Oncology.

Select news items provided by Reuters Health